Medications for neurodegenerative diseases

7,735views

Medications for neurodegenerative diseases

NMSK 2022

NMSK 2022

Anatomical terminology
Introduction to the central and peripheral nervous systems
Introduction to the somatic and autonomic nervous systems
Development of the axial skeleton
Bones of the vertebral column
Joints of the vertebral column
Muscles of the back
Vessels and nerves of the vertebral column
Anatomy clinical correlates: Bones, joints and muscles of the back
Superficial structures of the neck: Posterior triangle
Deep structures of the neck: Root of the neck
Anatomy clinical correlates: Vessels, nerves and lymphatics of the neck
Bones of the upper limb
Development of the limbs
Fascia, vessels and nerves of the upper limb
Muscles of the hand
Anatomy of the arm
Anatomy of the brachial plexus
Brachial plexus
Bones of the lower limb
Fascia, vessels and nerves of the lower limb
Muscles of the gluteal region and posterior thigh
Compartment syndrome
Sciatica
Bone remodeling and repair
Ectoderm
Skin histology
Skin anatomy and physiology
Skin and soft tissue infections: Clinical
Papulosquamous and inflammatory skin disorders: Pathology review
Eczematous rashes: Clinical
Skin cancer: Pathology review
Skin cancer: Clinical
Bone histology
Skeletal system anatomy and physiology
Bone disorders: Pathology review
Bone tumors: Pathology review
Paget disease of bone
Pediatric bone and joint infections: Clinical
Joint pain: Clinical
Gout
Rheumatoid arthritis
Nervous system anatomy and physiology
Neuromuscular junction and motor unit
Neuromuscular blockers
Skeletal muscle histology
Muscular system anatomy and physiology
Muscle contraction
Sliding filament model of muscle contraction
Muscle spindles and golgi tendon organs
Neuromuscular junction disorders: Pathology review
Muscle weakness: Clinical
Sympathetic nervous system
Parasympathetic nervous system
Adrenergic receptors
Cholinergic receptors
Opioid agonists, mixed agonist-antagonists and partial agonists
Cholinomimetics: Direct agonists
Substance misuse and addiction: Clinical
Pharmacodynamics: Desensitization and tolerance
Bones of the cranium
Anatomy of the cranial base
Anatomy of the orbit
Anatomy of the eye
Photoreception
Fascia and spaces of the neck
Superficial structures of the neck: Anterior triangle
Eye conditions: Inflammation, infections and trauma: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Pharyngeal arches, pouches, and clefts
Development of the face and palate
Development of the nervous system
Anatomy of the brainstem
Broca aphasia
Wernicke aphasia
Memory
Cerebrospinal fluid
Normal pressure hydrocephalus
Anatomy of the blood supply to the brain
Introduction to the cranial nerves
Cranial nerves
Cranial nerve pathways
Spina bifida
Congenital neurological disorders: Pathology review
Meningitis, encephalitis and brain abscesses: Clinical
Meningitis
Brain abscess
Encephalitis
Spinal cord disorders: Pathology review
Sensory receptor function
Somatosensory receptors
Anatomy of the ascending spinal cord pathways
Anatomy of the descending spinal cord pathways
Anatomy clinical correlates: Spinal cord pathways
Somatosensory pathways
Vitamin B12 deficiency
Motor cortex
Pyramidal and extrapyramidal tracts
Brown-Sequard Syndrome
Syringomyelia
Cauda equina syndrome
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Amyotrophic lateral sclerosis
Olfactory transduction and pathways
Trigeminal neuralgia
Bell palsy
Optic pathways and visual fields
Pituitary adenoma
Anatomy of the oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Anatomy clinical correlates: Oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Vestibulo-ocular reflex and nystagmus
Vestibular transduction
Cerebellum
Dizziness and vertigo: Clinical
Basal ganglia: Direct and indirect pathway of movement
Essential tremor
Huntington disease
Parkinson disease
Movement disorders: Pathology review
Anti-parkinson medications
Medications for neurodegenerative diseases
Hypokinetic movement disorders: Clinical
Multiple sclerosis
Leukodystrophy
Sleep
Toxidromes: Clinical
Cerebral vascular disease: Pathology review
Saccular aneurysm
Intracerebral hemorrhage
Arteriovenous malformation
Ischemic stroke
Transient ischemic attack
Anatomy clinical correlates: Posterior blood supply to the brain
Stroke: Clinical
Epidural hematoma
Brain herniation
Traumatic brain injury: Clinical
Traumatic brain injury: Pathology review
Concussion and traumatic brain injury
Adult brain tumors
Brain tumors: Clinical
Cluster headache
Tension headache
Migraine
Cavernous sinus thrombosis
Idiopathic intracranial hypertension
Migraine medications
Antidiuretic hormone
Hypoprolactinemia
Growth hormone and somatostatin
Oxytocin and prolactin
Anatomy of the limbic system
Frontotemporal dementia
Dementia with Lewy bodies
Vascular dementia
Creutzfeldt-Jakob disease
Syncope: Clinical
Amnesia

Transcript

Watch video only

Huntington disease, or HD, is a rare neurodegenerative disease that involves a repeated sequence of DNA that causes an abnormal protein to form, leading to abnormal movements and cognitive problems.

In most people, a gene called huntingtin or HTT on chromosome 4, contains a triplet repeat, where the nucleotides C, A, and G are repeated 10-35 times in a row. In people with Huntington disease, this repeat goes on for 36 or more times in a row.

CAG codes for the amino acid glutamine, so people with Huntington disease will have 36 or more glutamines in a row in the huntingtin protein.

So, in addition to being a triplet repeat disorder, HD is, more specifically, a “polyglutamine” disease.

The specific way in which extra glutamines causes HD symptoms isn’t fully worked out, but some clues are that the mutated protein aggregates within the neuronal cells of the caudate and putamen of the basal ganglia causing neuronal cell death.

Cell death might be related to excitotoxicity, which is excessive signaling of these neurons, which leads to high intracellular calcium.

Now the symptoms of HD involve progressive CNS disturbances including movement, cognitive, and mood symptoms and they start appearing around the age of 40.

Remember, the age of onset depends on the number of CAG repeats, so more repeats means earlier onset.

Over time, if enough of the neurons die in the caudate and putamen, which together form the dorsal striatum, then it can cause actual loss of brain tissue volume in that area and expansion of the lateral ventricles.

The death of neurons also cause neurotransmitter imbalance in these regions and there’s a decrease in inhibitory neurotransmitters like GABA, and an increase in stimulatory neurons like dopamine.

This also decreases acetylcholine, which is released by interneurons that help other neurons communicate.

Now, the affected areas play an important role in movement, particularly inhibiting it, so cell death in the basal ganglia causes movement problems like chorea, which are purposeless, dance-like jerking movements, and athetosis which are slower, writhing, “snake-like” movements mainly affecting the hands.

These involuntary movements can’t be consciously suppressed and stop only with sleep.

Other motor problems include abnormal eye movements and poor coordination.

Loss of tissue in these regions can also lead to psychological problems as well.

These people often experience psychosis and agitation, leading to disruptive behavior, and mood disorders like major depressive disorder.

They might also develop dementia and severe cognitive defects.

Since the muscles for swallowing become discoordinated, these people often suffer from dysphagia and aspiration pneumonia.

Unfortunately, there is no treatment to stop or reverse Huntington disease, and death usually happens within 10-20 years of diagnosis, often by aspiration pneumonia or suicide.

The medications used for Huntington disease are focused around managing the symptoms like chorea, and psychosis.

Since dopamine is increased in the regions of the brain affected, medications that lower dopamine levels or act as antagonists are usually used. These include tetrabenazine, and antipsychotics.

Let’s start with tetrabenazine and its deuterated form, deutetrabenazine.

Deuterated simply means some of the hydrogen molecules in the medication have been replaced by the more stable deuterium isotope to improve the half life of the drug.

These medications work on both presynaptic and postsynaptic neurons.

In the presynaptic neuron, they block vesicular monoamine transporters, or VMAT found on the vesicles.

These transport proteins allow dopamine into the vesicles for storage, so when they are inhibited, the vesicles can’t release dopamine into the synaptic cleft.

Next, on the postsynaptic neuron, these medications act as a weak dopamine receptor antagonist, so they bind to the receptors and prevent dopamine from binding.

Tetrabenazine and deutetrabenazine are often used for the treatment of chorea in Huntington disease. However, they are also useful for treating Tourette’s syndrome, which is a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics.

Key Takeaways

There are a few different types of medications that can be prescribed for neurodegenerative diseases. One common type is called cholinesterase inhibitors, which work by preventing the breakdown of the neurotransmitter acetylcholine. This type of medication can help to improve cognitive function and memory in people with Alzheimer's disease.

Another common type of medication for neurodegenerative diseases is NMDA receptor blockers. This type of medication helps to prevent damage to nerve cells by blocking the action of glutamate, a chemical that can be harmful to nerve cells. Blocking glutamate can help to preserve nerve function and reduce symptoms in people with conditions such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Deuterium Tetrabenazine for Tardive Dyskinesia" Clin Schizophr Relat Psychoses (2018)
  5. "Huntington's Disease-Update on Treatments" Curr Neurol Neurosci Rep (2017)
  6. "Antipsychotic drugs in Huntington's disease" Expert Rev Neurother (2017)